JP2010540660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540660A5 JP2010540660A5 JP2010528167A JP2010528167A JP2010540660A5 JP 2010540660 A5 JP2010540660 A5 JP 2010540660A5 JP 2010528167 A JP2010528167 A JP 2010528167A JP 2010528167 A JP2010528167 A JP 2010528167A JP 2010540660 A5 JP2010540660 A5 JP 2010540660A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- mammal
- composition
- administration
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000124008 Mammalia Species 0.000 claims 6
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims 5
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 3
- 230000010437 erythropoiesis Effects 0.000 claims 3
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000052793 human TNFRSF14 Human genes 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99781807P | 2007-10-05 | 2007-10-05 | |
| PCT/US2008/078769 WO2009046313A2 (en) | 2007-10-05 | 2008-10-03 | Novel compositions and methods for stimulating erythropoiesis in a mammal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010540660A JP2010540660A (ja) | 2010-12-24 |
| JP2010540660A5 true JP2010540660A5 (enExample) | 2011-11-17 |
Family
ID=40526962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528167A Pending JP2010540660A (ja) | 2007-10-05 | 2008-10-03 | 哺乳類内の赤血球生成を刺激する新規の組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100203047A1 (enExample) |
| EP (1) | EP2195344A4 (enExample) |
| JP (1) | JP2010540660A (enExample) |
| CA (1) | CA2701608A1 (enExample) |
| WO (1) | WO2009046313A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011163506A2 (en) * | 2010-06-23 | 2011-12-29 | University Of Louisville Research Foundation, Inc. | Methods and kits for predicting a response to an erythropoietic agent |
| AU2016334051B2 (en) * | 2015-10-06 | 2023-10-26 | Alector Llc | Anti-TREM2 antibodies and methods of use thereof |
| HRP20230675T1 (hr) | 2017-08-03 | 2023-09-29 | Alector Llc | Anti-trem2 protutijela i postupci njihove uporabe |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830851A (en) * | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
| US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| US6291207B1 (en) * | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
| WO1998051346A1 (en) * | 1997-05-12 | 1998-11-19 | Smithkline Beecham Corporation | Human tumor necrosis factor receptor-like 2 (tr2) antibodies |
| EP1169352A4 (en) * | 1999-04-14 | 2005-05-04 | Smithkline Beecham Corp | ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| EP1336619A3 (en) * | 2002-02-19 | 2003-12-10 | Millenium Pharmaceuticals, Inc. | Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders |
| WO2003086301A2 (en) * | 2002-04-12 | 2003-10-23 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tr2 |
| WO2007001459A2 (en) * | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
| AU2003300184B8 (en) * | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
| MX2007005612A (es) * | 2004-11-12 | 2007-08-14 | Genentech Inc | Novedosas composiciones y metodos para el tratamiento de enfermedades inmuno relacionadas. |
| JP2009533057A (ja) * | 2006-04-14 | 2009-09-17 | アムジエン・インコーポレーテツド | エリスロポエチン受容体アゴニスト |
| WO2008146101A1 (en) * | 2007-06-01 | 2008-12-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ligands of hvem for treating hematologic malignancies and autoimmune diseases |
-
2008
- 2008-10-03 US US12/680,819 patent/US20100203047A1/en not_active Abandoned
- 2008-10-03 EP EP08836759A patent/EP2195344A4/en not_active Withdrawn
- 2008-10-03 WO PCT/US2008/078769 patent/WO2009046313A2/en not_active Ceased
- 2008-10-03 JP JP2010528167A patent/JP2010540660A/ja active Pending
- 2008-10-03 CA CA2701608A patent/CA2701608A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| CN111630070A (zh) | 三特异性蛋白质及使用方法 | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| JP2020522513A5 (enExample) | ||
| JP2018535948A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| TW202210507A (zh) | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 | |
| JP2014527814A5 (enExample) | ||
| FI3569620T3 (fi) | Ihmisen cgrp-reseptoria sitovat vasta-aineet | |
| JP7459058B2 (ja) | Cd137/her2二重特異性物質とpd-1系阻害物質とを含む併用療法およびその使用法 | |
| CN105324396A (zh) | 针对IL-1β和/或IL-17的双重特异性结合蛋白 | |
| JP2019510739A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| US20220017617A1 (en) | Efficiently expressed egfr and pd-l1 bispecific binding proteins | |
| WO2014149733A1 (en) | Pan-ELR+ CXC CHEMOKINE ANTIBODIES | |
| JP2020502219A5 (enExample) | ||
| WO2018067819A1 (en) | Compositions and methods for treatment of cancers | |
| JP6933724B2 (ja) | Nk細胞活性化融合タンパク質、nk細胞およびそれらを含む医薬組成物 | |
| JP2018512402A5 (enExample) | ||
| CN109152814A (zh) | 方法、方案、组合和拮抗剂 | |
| HRP20161096T1 (hr) | Antigenski vežući proteini specifični za komponentu p serumskog amiloida | |
| US20150110788A1 (en) | Bispecific antibodies with an fgf2 binding domain | |
| JP2010540660A5 (enExample) | ||
| JP2020502218A5 (enExample) |